Carol Aghajanian, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses several new therapies she and her colleagues are developing to enhance the effectiveness of chemotherapy for ovarian cancer. These novel approaches target a variety of biological and genetic factors that contribute to the disease.